Member Info for stephen11

Not as yet John my friend.

I think it was Padrock who wisely pointed out that they may not want to publish the July production figures, as they could be market sensitive.

I’m expecting an NHS/sales RNS with some meat on the bones.

This share fly come good and fly past 10p - heavily manipulated by the mms at present.

Lots of planning going on in the background I’m sure 👌.

We know production of the tests were significantly increased in May/June.

Nice accreditation has been a cert for a while.

Machines and tests will be at the ready to distribute throughout the UK.

GLA.

Stephen11.

The lab tests come back between 2-5 days - it’s in one of the NICE docs.

Totally unfit for purpose as patients are at a higher risk of secondary stroke in this critical time period - they need Clopidigrel, or an alternative if the GDR test determines they are allergic to it.

GDR turnaround is 1 hour and results can link to patient NHS computer data 📈

Go GDR……….

---CYP2C19 - ID Kit---

- JC states at the last presentation that there is no reason why the CYP2C19 test will not get full recommendation in July....AND HE WAS RIGHT!!!!

- The world market is worth over £200m per annum

- UK Market £8.5m/ EU £93.5m/ US £67.5m/ RoW £51m

- CE-IVD marking in application process to open the European market

- Some interested parties want to use the CYP2C19 test on a research only basis around Europe

- Stroke incidence on the increase around the UK and predicted to increase by 60% between 2015 and 2035 (due to obesity and ageing population)

- The turnaround time for the labs is 2 days at the earliest - NICE says the test is time critical and must be done much earlier, as stroke patients are at risk off another stroke at this time

---MTRNR-1 AHIL (Antibiotic Induced Hearing Loss) ---

- Approximately 100 thousand UK neo-natal admissions per year (GDRs potential market)

- Market valued at +£100m worldwide

- UK 8.5m/ EU £46m/ US £34m/ RoW £13.75m

- Already has the CE-IVD cert to sell in EU, Europe, and the world

- EVA evidence generation in place to help achieve full NICE accreditation

- Specialist commissioning is scheduled for April 2025 - though GDR are campaigning for this to happen sooner

£5m cash in the bank and a revenue of at least £8.5m a year starting in August/September 2024

An MCAP of £22.27m - massively undervalued when you consider that GDR are on the cusp of real commercial traction.

GLA.

Stephen11.

I am sure this is not the only marketing activity going on.

Watch the latest investormeetcompany update from the 5/4/2024.

https://youtu.be/gUjy3cAjV5M

It details all the near term news.

You should a politician StockSaint, the amount of selective and misinformation you post - people see that now.

it’s not stocksaint.

you’re talking rubbish again.

the message is sent from prof. john mcdermott who has ran the studies, from manchester university you donut 🍩.

thanks again muck.

# take no **** 💩 from stocksaint aka starres (before he got banned).

Thanks for sharing Muck165 😉.

As so many have correctly predicted, commercial traction is just around the corner.

There it is in black and white, as shared.

Transformational news.

Genuinely pleased for everyone.

GLA.

Stephen11.

You haven’t drank enough yet Joey

Never worry about GDR - it’s only a share

Why all the bedwetting.

This will come good soon.

In the mean time, chill out and book another holiday.

31-Jul-24 15:38:07 4.1113 1,101,546 Unknown* 4.05 4.10 45.29k O

31-Jul-24 15:37:35 4.122 1,325,000 Unknown* 4.05 4.10 54.62k O

Almost £100, 000 in two transactions!

NICE!

You’re one to go correcting people StockSaint!

Most of your ridiculous theories have been debunked by this mornings RNS.

You’ll be telling us Elvis is still alive and playing in Benidorm next.

I would love some private institutions to buy in - it would stabilise the share price.

The high percentage of private investors at present leaves GDR at the hands of the MMs.

Now that we have a potential sales stream the big institutions might take GDR more seriously.

I agree RP2020.

GDR and KOD are the best prospects on AIM atm.

...

MAKE THE MMs work - this share has been manipulated for months. DON'T give away your shares cheaply.

Find out why below:

I've seen a few people ask why they should invest in GDR.

Here's a summary of why I've been here for 4 years and why i believe the transformational news on Wed will only be the tip of the iceberg.

---CYP2C19 - ID Kit---

- JC states at the last investormeetcompany presentation that there is no reason why the CYP2C19 test will not get full recommendation in July....AND HE WAS RIGHT!!!!

- The world market is worth over £200m per annum

- UK Market £8.5m/ EU £93.5m/ US £67.5m/ RoW £51m

- CE-IVD marking in application process to open the European market

- Some interested parties want to use the CYP2C19 test on a research only basis around Europe

- Stroke incidence on the increase around the UK and predicted to increase by 60% between 2015 and 2035 (due to obesity and ageing population)

- The turnaround time for the labs is 2 days at the earliest - NICE says the test is time critical and must be done much earlier, as stroke patients are at risk off another stroke at this time

---MTRNR-1 AHIL (Antibiotic Induced Hearing Loss) ---

- Approximately 100 thousand UK neo-natal admissions per year (GDRs potential market)

- Market valued at +£100m worldwide

- UK 8.5m/ EU £46m/ US £34m/ RoW £13.75m

- Already has the CE-IVD cert to sell in EU, Europe, and the world

- EVA evidence generation in place to help achieve full NICE accreditation

- Specialist commissioning is scheduled for April 2025 - though GDR are campaigning for this to happen sooner

£5m cash in the bank and a revenue of at least £8.5m a year starting in August/September 2024

An MCAP of £22.27m - massively undervalued when you consider that GDR are on the cusp of real commercial traction.

GLA.

Stephen11.

Thanks PadRock - as you say - GDR don't want to show there hand until the sales RNS

.

Also, has anyone checked the production numbers for the tests for July.

I know the production was significantly bumped up in June after seeing the company health+safety/compliance sign-off